18 October 2023
18 October 2023
The Clinical Trials Arena team also review assets in oncology, autoimmune disorders and neurological disorder indications.
Tremfya demonstrated 54.1% of clinical remission in patients with moderate-to-severe Crohn’s disease.
Teva’s Ajovy reduced monthly migraine days and depression symptoms in patients with major depressive disorder.
The company will also conduct a second Phase II trial with its combo therapy CuraCN in Parkinson’s disease patients.
The data from the Phase II trial showed the efficacy of tipifarnib in patients with recurrent/metastatic head and neck squamous cell carcinoma.
The first patient in the trial is expected to be enrolled in the first half of next year.
Patients in the first phase of the study will be given CTO1681 10μg before receiving their CAR T-cell therapy.
Top-line interim data from the trial is anticipated in mid-2024.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
